Core Viewpoint - Genting New Year Limited (1952.HK) successfully held a special shareholders' meeting on February 24, 2026, where all proposed resolutions were formally approved by shareholders [1] Group 1: Shareholder Meeting Outcomes - The special shareholders' meeting approved, confirmed, and ratified the commercialization service agreement signed with Haisen Biotechnology on December 11, 2025, along with related transactions to support the company's subsequent commercialization operations and business advancement [1] - The meeting also approved the granting of incentive arrangements to the company's management and adopted the 2026 share plan and related authorization limits [1] - The high approval rates for these resolutions reflect investors' recognition of the company's strategic direction and governance, which will support the ongoing commercialization layout and long-term development strategy [1] Group 2: Strategic Partnerships - The collaboration with Haisen Biotechnology is expected to enhance the operational efficiency of the existing commercialization platform and accelerate the construction of product lifecycle and multi-channel coverage capabilities [1]
云顶新耀股东特别大会通过商业化服务协议等决议案